none6noImmune Check-Point Inhibitors (CPIs) have improved long-term patients’ outcomes in several advanced cancers. Diabetes mellitus induced by CPIs (CPI-DM) is considered the second most frequent endocrine CPIs’ side effects with a variable prevalence up to 2%. The aim of our study was to identify CPI-DM characteristics and differences from the classical form of diabetes. Therefore, we conducted a structured Pubmed® search collecting publications dated from January 2015 to December 2019. A total of 642 citations were identified and 121 publications met our study criteria. We analyzed 200 case reports, including our 3 cases under publication. The majority of CPI-DM occurred with anti-Programmed cell Death-1 in monotherapy or in combination...
AIMS: Programmed cell death-1 and programmed death ligand 1 (PD-1/PD-L1) inhibitors restore antitumo...
The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several canc...
BACKGROUND Checkpoint inhibitors are relatively new anti-cancer medicines that activate tumour cell ...
none6noImmune Check-Point Inhibitors (CPIs) have improved long-term patients’ outcomes in several ad...
Immune checkpoint inhibitors (CPI) are increasingly being used in oncology, and many autoimmune side...
Objective: To better define the rare adverse event (AE) of diabetes mellitus associated with immune ...
Pembrolizumab is an anti-cancer drug that targets programmed cell death protein-1 (PD-1) receptors o...
Immune checkpoint inhibitor-induced diabetes mellitus is a rare immune-related adverse event. This r...
Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibi...
Checkpoint inhibitors (CPIs) targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) a...
With the increasing use of immune-checkpoint inhibitors (ICIs), such as anti-cytotoxic T lymphocyte-...
BACKGROUND: In recent years, immune checkpoint blockade has become a standard therapy for a wide ran...
AIMS: We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoi...
Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at the price...
Immune checkpoint inhibitor (ICI)- and phosphatidylinositol-3-kinase inhibitor (PI3Ki)-related diabe...
AIMS: Programmed cell death-1 and programmed death ligand 1 (PD-1/PD-L1) inhibitors restore antitumo...
The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several canc...
BACKGROUND Checkpoint inhibitors are relatively new anti-cancer medicines that activate tumour cell ...
none6noImmune Check-Point Inhibitors (CPIs) have improved long-term patients’ outcomes in several ad...
Immune checkpoint inhibitors (CPI) are increasingly being used in oncology, and many autoimmune side...
Objective: To better define the rare adverse event (AE) of diabetes mellitus associated with immune ...
Pembrolizumab is an anti-cancer drug that targets programmed cell death protein-1 (PD-1) receptors o...
Immune checkpoint inhibitor-induced diabetes mellitus is a rare immune-related adverse event. This r...
Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibi...
Checkpoint inhibitors (CPIs) targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) a...
With the increasing use of immune-checkpoint inhibitors (ICIs), such as anti-cytotoxic T lymphocyte-...
BACKGROUND: In recent years, immune checkpoint blockade has become a standard therapy for a wide ran...
AIMS: We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoi...
Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at the price...
Immune checkpoint inhibitor (ICI)- and phosphatidylinositol-3-kinase inhibitor (PI3Ki)-related diabe...
AIMS: Programmed cell death-1 and programmed death ligand 1 (PD-1/PD-L1) inhibitors restore antitumo...
The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several canc...
BACKGROUND Checkpoint inhibitors are relatively new anti-cancer medicines that activate tumour cell ...